Who are BFF MDI (PT009)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trimbow pMDI, Budesonide/formoterol and tiotropium, CHF 5993 100/6/12.5 µg, Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium, Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium, BDP/FF/GB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bff-mdi-pt009.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BFF MDI (PT009) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BFF MDI (PT009) (BFF MDI (PT009)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist. Area: Respiratory/Pulmonology.

phase 3 Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

BFF MDI (PT009) (BFF MDI (PT009)) — Pearl Therapeutics, Inc.. BFF MDI is a combination inhaled therapy containing budesonide, formoterol, and glycopyrronium that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BFF MDI (PT009) TARGET	BFF MDI (PT009)	Pearl Therapeutics, Inc.	phase 3	Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Trimbow pMDI	Trimbow pMDI	Medicines Evaluation Unit Ltd	marketed	Triple combination inhaler (ICS/LABA/LAMA)	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Budesonide/formoterol and tiotropium	Budesonide/formoterol and tiotropium	Brian J Lipworth	marketed	Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
CHF 5993 100/6/12.5 µg	CHF 5993 100/6/12.5 µg	Chiesi Farmaceutici S.p.A.	phase 3	ICS/LABA/LAMA combination	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium	Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium	Chiesi Farmaceutici S.p.A.	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium	Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium	Chiesi Farmaceutici S.p.A.	phase 3	Triple-combination inhaler (ICS/LABA/LAMA)	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
BDP/FF/GB	BDP/FF/GB	Chiesi Farmaceutici S.p.A.	phase 3	Triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA)	Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist class)

Pearl Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BFF MDI (PT009) — Competitive Intelligence Brief. https://druglandscape.com/ci/bff-mdi-pt009. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing